宝济药业(02659.HK)KJ103用于肾移植脱敏治疗III期临床试验完成随访 将提交新药上市申请

阿斯达克财经
Yesterday

宝济药业(02659.HK) 公布,KJ103作为脱敏疗法用于中国等待肾脏移植的高敏感患者的III期临床试验,已于今年3月20日完成所有入组受试者的主要试验随访。公司将尽快向国家药监局提交新药上市申请。KJ103是一款全球首创、低免疫原性创新重组免疫球蛋白G(IgG)降解酶,用于治疗由病理性IgG抗体驱动的多种免疫介导疾病及病症。(sl/da)(港股报价延迟最少十五分钟。)AASTOCKS新闻

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10